Clinical Trial

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Name: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — clinical trial record (NCT06830629)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Protocol Amendment History 2 changes

notable Enrollment increased: 56 -> 74 participants 2026-07-28

notable Trial sites expanded: 73 -> 81 locations 2026-04-18

Trial Details

NCT Number	NCT06830629
Lead Sponsor	Maze Therapeutics
Conditions	Proteinuric Kidney Disease
Enrollment	74 participants
Start Date	2025-02-05
Primary Completion	2026-09 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-27